Original Research
Published on 10 Jan 2025
Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1512339
- 668 views
Type at least 3 characters
1,047 articles
Systematic Review
Published on 08 Jan 2025
Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1487376
- 877 views
Review
Published on 07 Jan 2025
Selenium in cancer management: exploring the therapeutic potential
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1490740
- 1,780 views
- 1 citation
Case Report
Published on 24 Dec 2024
Case report: Eczematous adverse drug reaction after selpercatinib treatment
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1475541
- 676 views
- 1 citation
Review
Published on 16 Dec 2024
Research progress of novel anti-tumor drug formulations
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1507958
- 974 views
Case Report
Published on 13 Dec 2024
Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1453259
- 840 views
- 1 citation
Review
Published on 11 Dec 2024
The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1506588
- 1,309 views
Correction
Published on 06 Dec 2024
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1532291
- 447 views
Editorial
Published on 06 Dec 2024
Editorial: Photodynamic therapy: challenges and innovations for treating cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1526550
- 407 views
Original Research
Published on 05 Dec 2024
Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1422039
- 860 views
Original Research
Published on 05 Dec 2024
Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1485594
- 860 views
Correction
Published on 03 Dec 2024
Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1515205
- 471 views
Editorial
Published on 02 Dec 2024
Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1508214
- 485 views
Correction
Published on 27 Nov 2024
Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1472829
- 384 views
Correction
Published on 25 Nov 2024
Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1501882
- 867 views
Review
Published on 25 Nov 2024
Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1481777
- 1,297 views